Champion the evolution of People & Culture department in a rapidly growing, clinical-stage biotech dedicated to disruption of the treatment paradigm in immune-mediated diseases including lupus and psoriasis. Transitioned from Head of Program and Portfolio Management after invitation from CEO to step into Chief People Officer role.
• Establish a compelling and value-creating people vision aligned with scientific, clinical & operational company strategy.
• Drove FTE growth by 72% to 190 employees over 2 years with minimal turnover and 98% corporate goal achievement.
• Build impactful, integrated capabilities in People Ops, Talent Acquisition, Leadership Development, and Engagement.
• Refined high-complexity compensation framework through IPO and merger with similarly sized biotech organization.

Established a fit-for purpose, scalable pipeline Program & Portfolio Management infrastructure right-sized to operating model enabling efficient and disciplined advancement, derisking and value creation of early-stage small-molecule assets focused on immune-mediated disease.
• Articulated enterprise-level functional vision & org design. Built a capable and diverse PM team from scratch.
• Designed and implemented Project Team system enabling rapid transition of TYK2 inhibitor into three Phase 2 studies.
• Conceived and implemented Portfolio Committee enabling clear decision-making and alignment on pipeline trade-offs.
• Led Alliance Management collaboration with Foresite Labs focused on developing autoimmune analytics platform.

Chief of Staff to Brisbane Site Head Championed Project Management excellence as global Program Management Head for one of 5 Therapeutic Areas while leading operational and cultural site integration into BMS infrastructure.
• Drove NDA filing of CAMZYOS® resulting in first-in-class FDA approval for oHCM indication in April of 2022.
• Advanced a Phase 2 & Phase 3 CV portfolio of cardiomyopathy & thrombosis assets also driving over $9B in revenue.
• Effectively managed a team of 6 Project Managers resulting in multiple successful trial readouts in CV disease.

Evolved and expanded the capabilities of a rapidly growing Project Management function in a clinical-stage small-molecule biotech focused on precision medicine approaches addressing genetic cardiomyopathies and heart failure.
• Set vision, strategy & operational framework for a diversified PM function during accelerated growth phase.
• Directly managed a team of 8 project managers resulting in accelerated Phase 1 – Phase 3 clinical development, improved commercial launch readiness, focused and efficient governance decisions and design of post-market registry.
● Project Management Consultant (Richardson Consulting, LLC) Oct 2018 – Apr 2020 Provided PM, BD & Alliance Management services to shape company strategy, organize and drive multiple complex activities focused on advancing a small molecule cardiomyopathy clinical-stage drug pipeline.
• Effectively led Mavacamten cross-functional teams resulting in initiation of HCM, SRT & HFpEF late-stage trials.
• Integrated Digital Health w

Provided PM, Operational Excellence and strategic management support for global manufacturing business unit responsible for reliable supply of 20+ marketed biologics in multiple disease areas including inflammatory & oncology.
• Chief of Staff to Head of Drug Substance & Drug Product Technical Leads accountable for manufacturing life-cycle.
• Provided consultative support, coaching and implementation of PM tools and techniques to a global function.

Built a Project Management function as a core capability within a niche medical device contract manufacturing firm.
• Reported to CEO and directly managed a team of 10 technically oriented, customer facing Project Managers.
• Organized and drove technically complex activities for a portfolio of over 40 complex nickel-titanium devices used in numerous clinical spaces including structural heart repair, electrophysiology, and peripheral vascular disease.

Provided PM leadership driving the advancement of novel monoclonal antibodies focused on treatment of cancer and multiple sclerosis as AbbVie brand spun out of Abbott.
• Developed and managed comprehensive portfolio-level strategies & detailed plans for Phase 1 – Phase 3 molecules.
• Led cross-functional teams driving Phase 2 trials in cMet, VEGF and DLL4 including a DVD bi-specific and an ADC.
• Alliance PM and Asset Team Manager for large Phase 3 multiple sclerosis co-development with Biogen-Idec.

Strategized and developed several disposable & reusable devices in a novel surgical lighting technology portfolio.
• Developed multiple class II orthopedic surgical lighting devices leveraging precision injection molded optics.
• Managed engineering development and IP in a 10-person, venture backed start-up.

Championed the revival of a technical team within a small medical device start-up that underwent a significant downsizing due to a change in clinical focus.
• Managed a group of engineers developing a complex NOTES robotic endoscope in a challenging turn-around situation.
• Successfully completed complex prototype proof-of-concept testing on human cadavers ahead of schedule.

Director, Stent Engineering Led a small technical team focused on refining and commercializing a novel combination device coronary implant system enabling targeted, controlled drug release.
• Worked closely with founder and CTO to drive CAD design, FEA, rapid prototyping and bench/animal testing
• Contributed to LCM strategies and evaluation of new business opportunities
EARLY CAREER